AbbVie, Genmab Get Speedy FDA Review of Epkinly in Follicular Lymphoma
By Colin Kellaher
AbbVie and Genmab have won U.S. Food and Drug Administration priority review for their application seeking expanded approval of Epkinly in certain patients with hard-to-treat follicular lymphoma.
The companies on Tuesday said the application covers adults with relapsed or refractory follicular lymphoma after two or more lines of therapy.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. The agency has set a target action date of June 28 for the application.
AbbVie and Genmab said Epkinly, if approved, would be the first and only subcutaneous bispecific antibody to treat adults with relapsed or refractory follicular lymphoma after two lines of prior therapy.
North Chicago, Ill., biopharmaceutical company AbbVie and Copenhagen biotechnology company Genmab are co-developing Epkinly under a 2020 collaboration.
The FDA and European regulators previously approved the drug for third-line treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 27, 2024 08:27 ET (13:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month